Investigational drug · Phase 3
Zinlirvimab
Also called: GS-2872, ZAB
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1 Infection, HIV Infections, HIV-1-infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "Zinlirvimab"
First trial start
2023
May 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zinlirvimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1 Infection
- HIV Infections
- HIV-1-infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Zinlirvimab" as an intervention, largest first.
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07683000 · 590 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 3 more · For: HIV-1-infection
Sites: Berkeley, Michigan; Annandale, Virginia
- A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05729568 · 83 participants · Start May 15, 2023 · Primary completion Jul 2, 2024
Drug: Teropavimab; Zinlirvimab and 3 more · For: HIV-1 Infection
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 34 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06071767 · 36 participants (planned) · Start Apr 1, 2024 · Primary completion Apr 29, 2028
Drug: ChAdOx1.tHIVconsv1; ChAdOx1.HIVconsv62 and 7 more · For: HIV-1-infection
Sites: San Diego, California; Atlanta, Georgia; Chicago, Illinois · 11 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT04811040 · 32 participants · Start Apr 8, 2021 · Primary completion Jun 9, 2022
Drug: Oral Lenacapavir; Subcutaneous Lenacapavir and 2 more · For: HIV-1 Infection
Sites: Los Angeles, California; Sacramento, California; San Diego, California · 23 sites in all
- Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1Pivotal-lookingNot yet recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07947732 · 25 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Lenacapavir Tablet; Lenacapavir Injection and 2 more · For: HIV-1-infection
Sites: The Bronx, New York; Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- In situ growth of covalent organic frameworks on the surface of Cu-MOF derivatives boosting self-powered electrochemical sensor.
Ying T, Liu J, Liang J, et al. · Talanta 2027
- Dealloying-engineered nanoporous Ag-Pt solid-solution alloys with synergistic dual sites for efficient oxygen reduction and zinc-air battery applications.
Xu H, Zhang Y, Zhao Y, et al. · J Colloid Interface Sci 2027
- Band structure optimization and interface engineering of porphyrin-based covalent organic polymer heterojunction for boosted oxygen electrocatalysis in zinc-air batteries.
Zhuo H, Liu Q, Liu X, et al. · J Colloid Interface Sci 2027
- Boosting zinc-air battery performance through interface-engineered N-C/g-C3N4 photoelectric synergy.
Wang M, Yang Y, Zhang Y, et al. · J Colloid Interface Sci 2027
- Plasma-driven exsolution-sulfidation creates CoS2/perovskite heterostructures for flexible zinc-air batteries.
Zhang W, Zhang N, Deng X, et al. · J Colloid Interface Sci 2026
- Phosphorus-induced 0D/1D intertwined N, P-codoped Fe-N-C hierarchical architectures for highly stable zinc-air batteries.
Wang L, Guo Y, Zhao W, et al. · J Colloid Interface Sci 2026
Also in development for HIV-1 Infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- ISLPhase 33 trials
Merck & Co. · HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ULOMK-8507, UlonivirinePhase 33 trials
Merck & Co. · Human Immunodeficiency Virus Type 1 (HIV-1) Infection, HIV-1 Infection
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- CL-197Phase 21 trial
Henan Genuine Biotech Co., Ltd. · HIV-1 Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.